Forest Laboratories has agreed to pay US$25 M upfront to co-fund and co-develop Nabriva Therapeutics’ pleuromutilin antibiotic BC-3781 over the next 12 months. The drug candidate has potential utility in the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia and Phase III trials are planned for 2013. The agreement also provides Forest with an exclusive option to acquire Nabriva during the 12-month period, subject to certain unspecified contingencies.